IDEMIA
23.2.2018 16:59:12 CET | Business Wire | Press release
IDEMIA, the global leader in Augmented Identity for an increasingly digital world, announces today that it has implemented facial recognition technology on EasyOpen, a solution previously developed with its partner Omoove, a wholly-owned Octo Telematics company, Europe’s leading Shared Mobility technology provider. The digital enrolment process combined with facial recognition technology will securely enroll and authenticate the driver before EasyOpen automatically opens the car.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180223005506/en/
You will never rent a car the same way thanks to EasyOpen solution that combines IDEMIA’s expertise in secure service enablement and Omoove’s experience in Shared Mobility platforms and on-board technology.
The first version of the solution was launched last year and allows drivers, who have already registered on the application, to use their smartphones as a key to open their cars in a secure way.
This year, both companies have just announced the introduction of a new process for the digital enrollment of the driver combined with facial recognition technology, which will be implemented into EasyOpen solution.
This solution uses the smartphone to create the identity of the driver by registering ID documents in a fast and user-friendly way, while afterwards granting access to the car through a selfie thanks to IDEMIA’s facial recognition solution.
According to a study run by Frost & Sullivan (www.frost.com ), car sharing users number should increase by 16,4% CAGR within 2025 : private car usage will then decrease and car rental agencies will need high performing technologies to secure shared cars. In that context, IDEMIA and Omoove strengthen their position on this promising market with the extremely simple, intuitive and fast EasyOpen solution. A demonstration of EasyOpen will take place at the Mobile World Congress 2018: end-to-end customer journey from registration on car rental application to opening of the car thanks to a selfie will be presented on this occasion on a Maserati Levante .
Yves Portalier, Executive Vice President of the Connected Objects business at IDEMIA declared: “After implementing a keyless solution last year, IDEMIA is now adding facial recognition technology to the end-user experience thus providing fast and secure registration and trusted online authentication. By combining increased security with additional convenience, we’re making the user experience even more simple in this promising car sharing market. ”
Giuseppe Zuco, CEO at Omoove and Octo Telematics co-founder, added: “We are pleased to participate once again with IDEMIA at the MWC; together with strengthening our partnership, we continue to share our expertise in automotive solutions and IoT applications. We look forward to showing a new mobility experience, through advanced biometrics and secure digital identity management. The keyless connected car will unveil a new era of shared Mobility, by simplifying the driver journey and allowing operators to offer a simple and reliable solution”.
No keys, no card, you only need a smartphone to open the car and
start the journey!
Discover the service at the Mobile World
Congress on IDEMIA ’s booth, Hall 6 Booth #6H30
Visit our virtual press room: http://mwc.vporoom.com/IDEMIA
About IDEMIA
OT-Morpho is now IDEMIA, the global leader in Augmented Identity for an increasingly digital world, with the ambition to empower citizens and consumers alike to interact, pay, connect, travel and vote in ways that are now possible in a connected environment.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable transactions for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
OT (Oberthur Technologies) and Safran Identity & Security (Morpho) have joined forces to form IDEMIA. With close to $3 billion in revenues and 14,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
About Octo Telematics
Octo is the number 1 global provider of telematics and data analytics
solutions for the auto insurance industry. Founded in 2002, Octo is one
of the pioneers of the insurance telematics industry. Today, Octo is the
largest and most experienced insurance telematics company in the world,
transforming auto insurance through behavioral, contextual and driving
analytics for more than 100 insurance partners.
Octo has more than
5.4 million connected users and the largest global database of
telematics data, with over 186 billion miles of driving data collected
and 438,000 crashes and insurance events analyzed (as of 31 December
2017).
Octo applies proprietary algorithms to this market-leading
database to deliver powerful new insights into driver risk, informing
solutions that benefit both auto insurance companies and policyholders.
The
company is headquartered in London, with offices in Boston, Rome,
Stuttgart, Madrid, and Sao Paulo.
For more information, visit www.octotelematics.com
About Omoove
Omoove is the European leader in providing innovative technological
solutions in the Mobility market, offering end-to-end Shared Mobility,
Fleet Management and Insurance Telematics technologies and solutions for
Vehicle Sharing Operators and Car Rental Companies.
Omoove operates
more than 10 car sharing services in 15 cities with about 200.000
connected vehicles and scooters, 900.000 registered users and more than
400.000 rentals per month (as of 31 December 2017). Founded in 2001,
Omoove is wholly-owned by Octo Telematics, the largest and most
experienced insurance telematics company in the world for number of
registered users and managed vehicles. Omoove is headquartered in Rome
with local offices in France, Spain, UK, Germany and the United States.
For more information, visit www.omoove.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180223005506/en/
Contact:
Press contacts
IDEMIA: Havas PR agency
Idemia@havas.com
+
33 6 63 73 30 30
or
OCTO TELEMATICS - OMOOVE
Adriana
Zambon
+39 339 3995640
press.it@octotelematics.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom